Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

Clin Infect Dis. 2023 Jan 13;76(2):338-341. doi: 10.1093/cid/ciac788.

Abstract

Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.

Keywords: Mycobacterium abscessus; Mycobacterium avium complex; adverse effects; antibiotic treatment; nontuberculous mycobacterial infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchiectasis* / drug therapy
  • Communicable Diseases*
  • Humans
  • Lung / microbiology
  • Lung Diseases* / microbiology
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium Infections, Nontuberculous* / epidemiology
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Mycobacterium avium Complex
  • Nontuberculous Mycobacteria
  • Opportunistic Infections*